0
     

Report Added
Report already added
Novartis AG - Strategy, SWOT and Corporate Finance Report

Novartis AG - Strategy, SWOT and Corporate Finance Report

Summary

Novartis AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company.

Key Highlights

Novartis AG (Novartis or ‘the company’) is the US based pharma company having presence in diverse biopharmaceutical segments. The company’s product portfolio includes surgicals, ophthalmic pharmaceuticals, vision care products, generic medicines and biosimilars. It provides products for cancer, cardio metabolic, cell and gene therapy. The company offers its products under Alcon, Azarga, Ciprodex, Cibacen, Cosentyx, Sandoz, Votrient, DAILIES, Clear Care, AIR OPTIX, FreshLook and Lucentis brands. It also conducts various research and development activities through its Novartis Institutes for BioMedical Research (NIBR). It has operations across Asia-Pacific, Europe, the Americas, and the Middle East and Africa. The company is headquartered in Basel, Switzerland.

Scope

- Detailed information on Novartis AG required for business and competitor intelligence needs
- A study of the major internal and external factors affecting Novartis AG in the form of a SWOT analysis
- An in-depth view of the business model of Novartis AG including a breakdown and examination of key business segments
- Intelligence on Novartis AG's mergers and acquisitions (MandA), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors
- News about Novartis AG, such as business expansion, restructuring, and contract wins
- Large number of easy-to-grasp charts and graphs that present important data and key trends

Reasons to Buy

- Gain understanding of Novartis AG and the factors that influence its strategies.
- Track strategic initiatives of the company and latest corporate news and actions.
- Assess Novartis AG as a prospective partner, vendor or supplier.
- Support sales activities by understanding your customers' businesses better.
- Stay up to date on Novartis AG's business structure, strategy and prospects.

Table of Contents

Company Snapshot
Novartis AG: Company Overview
Novartis AG: Overview and Key Facts
Novartis AG: Overview
Novartis AG: Key Facts
Novartis AG: Key Employees
Novartis AG: Key Employee Biographies
Novartis AG: Major Products and Services
Novartis AG: Company History
Novartis AG: Management Statement
Novartis AG: Locations and Subsidiaries
Novartis AG: Key Competitors
Novartis AG: Company Analysis
Novartis AG: Business Description
Novartis AG: SWOT Analysis
Novartis AG: SWOT Overview
Novartis AG: Strengths
Novartis AG: Weaknesses
Novartis AG: Opportunities
Novartis AG: Threats
Novartis AG: Corporate Financial Deals Activity
Novartis AG: Financial Deals Overview
Novartis AG: Targets and Partners
Novartis AG: Top Deals 2018 - 2022YTD*
Novartis AG: Advisors
Novartis AG: Top Legal Advisors
Novartis AG: Top Financial Advisors
Novartis AG: Mergers and Acquisitions
Novartis AG: Corporate Venturing
Novartis AG: Capital Raising
Novartis AG: Partnership
Novartis AG: Divestments
Novartis AG: Recent Developments
Novartis AG: News and Events Summary
Novartis AG: Financial Deals
Novartis AG: Financial Performance
Novartis AG: Red Flags/DistressSignals
Novartis AG: Regulatory and Legal Events
Novartis AG: Research & Development
Novartis AG: Strategy and Operations
Appendix
Contact Us
Methodology
About MarketLine

List Of Tables
Table 1: Novartis AG: Key Facts
Table 2: Novartis AG: Key Employees
Table 3: Novartis AG: Company History
Table 4: Novartis AG: Locations and Subsidiaries
Table 5: Novartis AG: Key Competitors
Table 6: Novartis AG: Deal Activity by Deal Type - Volume (TTM*)
Table 7: Novartis AG: M&A Activity by Geography (TTM*)
Table 8: Novartis AG: Deal Activity by Deal Type - Volume (2018 - YTD*2022)
Table 9: Novartis AG: M&A Average Deal Size - Value (US$m)
Table 10: Novartis AG: Targets and Partners
Table 11: Novartis AG: Top Deals 2018 - 2022YTD*
Table 12: Novartis AG: Legal Advisor Ranking by Value (US$m)
Table 13: Novartis AG: Financial Advisor Ranking by Value (US$m)
Table 14: Novartis AG: M&A Volume and Value Trend (2018 - YTD*2022)
Table 15: Novartis AG: M&A Activity by Geography (2018 - YTD*2022)
Table 16: Novartis AG: Corporate Venturing Volume and Value Trend (2018 - YTD*2022)
Table 17: Novartis AG: Corporate Venturing by Geography (2018 - YTD*2022)
Table 18: Novartis AG: Capital Raising Volume and Value Trend (2018 - YTD*2022)
Table 19: Novartis AG: Capital Raising by Deal Type (2018 - YTD*2022)
Table 20: Novartis AG: Partnership Volume and Value Trend (2018 - YTD*2022)
Table 21: Novartis AG: Partnership Trend by Deal Type (2018 - YTD*2022)
Table 22: Novartis AG: Divestments Volume and Value Trend (2018 - YTD*2022)
Table 23: Novartis AG: Divestments by Geography (2018 - YTD*2022)
Table 24: Novartis AG: News and Events Summary
Table 25: Novartis AG: Financial Deals
Table 26: Novartis AG: Financial Performance
Table 27: Novartis AG: Red Flags/DistressSignals
Table 28: Novartis AG: Regulatory and Legal Events
Table 29: Novartis AG: Research & Development
Table 30: Novartis AG: Strategy and Operations

List Of Figures
Figure 1: Novartis AG: Deal Activity by Deal Type - Volume (TTM*)
Figure 2: Novartis AG: M&A Activity by Geography (TTM*)
Figure 3: Novartis AG: Deal Activity by Deal Type - Volume (2018 - YTD*2022)
Figure 4: Novartis AG: M&A Average Deal Size - Value (US$m)
Figure 5: Novartis AG: M&A Volume and Value Trend (2018 - YTD*2022)
Figure 6: Novartis AG: M&A Activity by Geography (2018 - YTD*2022)
Figure 7: Novartis AG: Corporate Venturing Volume and Value Trend (2018 - YTD*2022)
Figure 8: Novartis AG: Corporate Venturing by Geography (2018 - YTD*2022)
Figure 9: Novartis AG: Capital Raising Volume and Value Trend (2018 - YTD*2022)
Figure 10: Novartis AG: Capital Raising by Deal Type (2018 - YTD*2022)
Figure 11: Novartis AG: Partnership Volume and Value Trend (2018 - YTD*2022)
Figure 12: Novartis AG: Partnership Trend by Deal Type (2018 - YTD*2022)
Figure 13: Novartis AG: Divestments Volume and Value Trend (2018 - YTD*2022)
Figure 14: Novartis AG: Divestments by Geography (2018 - YTD*2022)

Report Title: Novartis AG - Strategy, SWOT and Corporate Finance Report


Your Details
Valid Invalid number

SELECT A FORMAT

ADD TO CART BUY NOW

Related Report

US Bispecific Antibodies  Market & Clinical Pipeline Insight 2028

US Bispecific Antibodies Market & Clinical Pipeline Insight 2028

2023-2027 Vietnam Molecular Blood Typing, Grouping and Infectious Disease NAT Screening  Analyzers and Reagents--Transfusion Market Emerging Opportunities, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts for 40 Immunohematology and NAT Assays through 2027, Latest Technologies and Instrumentation Pipeline

2023-2027 Vietnam Molecular Blood Typing, Grouping and Infectious Disease NAT Screening Analyzers and Reagents--Transfusion Market Emerging Opportunities, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts for 40 Immunohematology and NAT Assays through 2027, Latest Technologies and Instrumentation Pipeline

2023-2027 Venezuela Molecular Blood Typing, Grouping and Infectious Disease NAT Screening  Analyzers and Reagents--Transfusion Market Emerging Opportunities, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts for 40 Immunohematology and NAT Assays through 2027, Latest Technologies and Instrumentation Pipeline

2023-2027 Venezuela Molecular Blood Typing, Grouping and Infectious Disease NAT Screening Analyzers and Reagents--Transfusion Market Emerging Opportunities, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts for 40 Immunohematology and NAT Assays through 2027, Latest Technologies and Instrumentation Pipeline

2023-2027 Uruguay Molecular Blood Typing, Grouping and Infectious Disease NAT Screening  Analyzers and Reagents--Transfusion Market Emerging Opportunities, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts for 40 Immunohematology and NAT Assays through 2027, Latest Technologies and Instrumentation Pipeline

2023-2027 Uruguay Molecular Blood Typing, Grouping and Infectious Disease NAT Screening Analyzers and Reagents--Transfusion Market Emerging Opportunities, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts for 40 Immunohematology and NAT Assays through 2027, Latest Technologies and Instrumentation Pipeline

2023-2027 United Arab Emirates Molecular Blood Typing, Grouping and Infectious Disease NAT Screening  Analyzers and Reagents--Transfusion Market Emerging Opportunities, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts for 40 Immunohematology and NAT Assays through 2027, Latest Technologies and Instrumentation Pipeline

2023-2027 United Arab Emirates Molecular Blood Typing, Grouping and Infectious Disease NAT Screening Analyzers and Reagents--Transfusion Market Emerging Opportunities, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts for 40 Immunohematology and NAT Assays through 2027, Latest Technologies and Instrumentation Pipeline

2023-2027 Ukraine Molecular Blood Typing, Grouping and Infectious Disease NAT Screening  Analyzers and Reagents--Transfusion Market Emerging Opportunities, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts for 40 Immunohematology and NAT Assays through 2027, Latest Technologies and Instrumentation Pipeline

2023-2027 Ukraine Molecular Blood Typing, Grouping and Infectious Disease NAT Screening Analyzers and Reagents--Transfusion Market Emerging Opportunities, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts for 40 Immunohematology and NAT Assays through 2027, Latest Technologies and Instrumentation Pipeline